ReviewClinical reviews in allergy & immunology2005
Anti-CD23.
Review in Clinical reviews in allergy & immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- The Nodding syndrome cerebrospinal fluid proteome: a lens into neurodevelopmental failure consistent with environmentally triggeredFrontiers in molecular neuroscience · 2026Article
- Intensity of CD23 expression on IgGThe journal of allergy and clinical immunology. Global · 2025Article
- Stunting as a Risk Factor for Asthma: The Role of Vitamin D, Leptin, IL-4, and CD23.Medicina (Kaunas, Lithuania) · 2022Review
- Lymphocyte Immunosuppression and Dysfunction Contributing to Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS).Shock (Augusta, Ga.) · 2021Review
- IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy.Frontiers in immunology · 2020Review
- Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.Scientific reports · 2018Article
- Roles of extracellular nucleotides and P2 receptors in ectodomain shedding.Cellular and molecular life sciences : CMLS · 2016Review
- Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.The Journal of allergy and clinical immunology · 2016Review
- Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- S1P-induced airway smooth muscle hyperresponsiveness and lung inflammation in vivo: molecular and cellular mechanisms.British journal of pharmacology · 2015Article
- The future of biologics: applications for food allergy.The Journal of allergy and clinical immunology · 2015Review
- Review
- Role of circulating lymphocytes in patients with sepsis.BioMed research international · 2014Review
- Conformational plasticity at the IgE-binding site of the B-cell receptor CD23.Molecular immunology · 2013Article
- Early alterations of B cells in patients with septic shock.Critical care (London, England) · 2013Observational
- Emerging roles for protein S-palmitoylation in immunity from chemical proteomics.Current opinion in chemical biology · 2013Review
- Deciphering the structure and function of FcεRI/mast cell axis in the regulation of allergy and anaphylaxis: a functional genomics paradigm.Cellular and molecular life sciences : CMLS · 2012Review
- Soluble CD23 controls IgE synthesis and homeostasis in human B cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Mast cells and company.Frontiers in immunology · 2012Article
- Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD23, the low-affinity immunoglobulin (Ig)E receptor (FcepsilonRII), is widely distributed on the surface of various human cells. CD23 mediates numerous IgE-related immune responses (including allergen focusing) by enhancing IgE antigen complex presentation, regulating IgE synthesis, influencing cell differentiation and growth of both B- and T-cells, and stimulating production of pro-inflammatory mediators from monocytes/macrophages, eosinophils, and even airway smooth muscle cells. Both membrane and soluble CD23 play an important role in allergic reactions. Cellular contacts and cytokines modulate its expression in a concerted manner as needed for allergic reactions. Expression of CD23 and soluble CD23 has been associated with allergic diseases. Targeting CD23 with monoclonal antibody (MAb) is a promising candidate therapy in allergic diseases. A newly developed agent known as Lumiliximab, which is an anti-CD23 MAb (Lumiliximab), was demonstrated to be a well-tolerated agent in a phase I clinical trial (a placebo-controlled study with allergic asthma). Adverse events were mild, and no relationship was apparent between the dose of Lumilixilab and the frequency, severity, or type of event. Sustained and dose-dependent decreases in mean serum total IgE concentrations were noted. The serum half-life of Lumilixilab increased from 2 to 10 d with increasing doses. Blocking antigen presentation, preventing costimulation signals, and reducing production of pro-inflammatory mediators are some of the potential mechanisms involved for anti-CD23 activity. Although the safety and clinical efficacy of Lumilixilab in allergic asthma and rhinitis require confirmation, the observed data imply that anti-CD23 is a promising candidate therapy option for future treatment of allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.